Aneesh Acharya, Vice President of Commercial, Molecular Instruments
Aneesh Acharya, Vice President of CommercialIn the field of drug development, perhaps the most precious commodity is a reliable supply of high-quality tissue samples collected from real-world patients. For any organization seeking to develop a novel treatment, qualifying the integrity of tissue samples is of utmost importance, as this forms the foundation of all decisions made during the lengthy and expensive drug development process.

Typically, scientists have turned to ACD’s RNAscope as the gold standard for gauging RNA quality, which can be a useful proxy for overall tissue integrity. However, it is not uncommon for RNAscope studies to result in discarding over 60 percent of tissue samples. RNAscope’s monopoly on RNA-ISH has shielded it from being scrutinized in detail, since there have been no viable alternatives in over a decade.

Molecular Instruments (MI), a biotech startup that spun out of the California Institute of Technology in 2018 on the promise of its patented, proprietary HCR™ Platform, is launching a revolutionary product that pledges to significantly enhance every workflow that today depends on RNAscope.

Molecular Instruments: Simplifying Spatial-Omics with HCR™ Amplification

The company’s new HCR™ RNA-CISH kits promise a trifecta of improvements over RNAscope – (1) significantly better performance due to the next-generation HCR™ Platform, (2) at least twice as fast a turnaround time, and (3) at least twice as affordable a price. The company already has beta sites at over 15 large sites around the US and is expanding daily. Critically, the team at MI has ensured that their products are fully compatible with all standard automation hardware in the industry.

In addition to the newest HCR™ RNA-CISH product, MI is planning to further expand the spatial imaging capabilities it offers through a next-generation HCR™ RNA-FISH product that will undergo beta testing in the coming months, as well as HCR™ IHC/IF products later in the year. The company strongly believes in the unique differentiation the HCR™ Platform enables and has planned a broad range of products that incorporate it.

We believe that RNA imaging will be a key part of health and medicine in the future and that researchers and clinicians require better, more capable tools to be able to take full advantage of that future. We’re excited to be entering at the forefront of the research tools space.

“We believe that RNA imaging will be a key part of health and medicine in the future and that researchers and clinicians require better, more capable tools to be able to take full advantage of that future. We’re excited to be entering at the forefront of the research tools space,” says Aneesh Acharya, Ph.D., Vice President of Commercial at MI.

MI is a rare biotech startup that markets and distributes kits today, rather than seeking investments for future reward. They are certainly a company to keep an eye on to see if they are able to execute on their raw potential.